🔎 Trials Near Me

Home › Leukemia › California

Leukemia clinical trials in California

28 studies for Leukemia are looking for participants at sites in California.

Cities in California

Pivotal Open-label Phase 3 Clinical Study of QTX-2101 in Adult Patients With Acute Promyelocytic Leukemia

  • Quetzal Site 1, Duarte
  • Quetzal Site 7, Los Angeles
  • Quetzal Site 5, Stanford
RecruitingPhase 3
Ages 18 to 71 · All sexes · Updated Sep 23, 2026 · NCT07504458

Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission

  • USC Norris Comprehensive Cancer Center, Los Angeles
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 16, 2026 · NCT06824168

(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis

  • City of Hope Comprehensive Cancer Center, Duarte
  • UCLA Medical Center, Los Angeles
  • Stanford Cancer Institute, Stanford
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 15, 2026 · NCT04996875

Autologous CD22 CAR T Cells Following Commercial CD19 CAR T Cells in B Cell Malignancies

  • Stanford University, Palo Alto
RecruitingPhase 1
Ages 1 to 25 · All sexes · Updated Sep 1, 2026 · NCT06408194

Cognitive Aftereffects of Neurotoxicity in Children and Young Adults With Relapsed/Refractory Hematologic Malignancies Who Receive CAR T-cell Therapy

  • Children s Hospital of Los Angeles, Los Angeles
RecruitingObservational studyHealthy volunteers welcome
Ages 5 and older · All sexes · Updated Aug 31, 2026 · NCT05237986

Study of QUAIL-100 in Pediatric and Young Adult Participants With High-Risk Hematologic Malignancies Who Have Received a Hematopoietic Stem Cell Transplantation

  • Lucille Packard Children's Hospital of Stanford University, Palo Alto
RecruitingPhase 1
18 Months – 39 Years · All sexes · Updated Aug 21, 2026 · NCT07573111

Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia

  • USC Norris Comprehensive Cancer Center, Los Angeles
  • UCLA Health - Bowyer Oncology Center, Los Angeles
  • UC Irvine Health Chao Family Comprehensive Cancer Center, Orange
  • and 1 more
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 20, 2026 · NCT06001788

Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML

  • University of California, Fresno, Clovis
  • University of California, San Diego, La Jolla
  • Cedars-Sinai Medical Center, Los Angeles
  • and 2 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Aug 20, 2026 · NCT07007312

AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia

  • Research Site, Duarte
  • Research Site, Los Angeles
  • Research Site, Palo Alto
RecruitingPhase 1/2
Ages 12 and older · All sexes · Updated Aug 19, 2026 · NCT06137118

Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL

  • Children's Hospital Los Angeles, Los Angeles
  • Children's Hospital Orange County, Orange
  • UCSF School of Medicine, San Francisco
RecruitingPhase 2
Ages 7 to 25 · All sexes · Updated Aug 19, 2026 · NCT05082519

AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas

  • Stanford University, Palo Alto
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 12, 2026 · NCT06340737

Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)

  • City of Hope, Duarte
  • Valkyrie Clinical Trials, Los Angeles
RecruitingPhase 1/2
Ages 13 to 90 · All sexes · Updated Aug 6, 2026 · NCT06533579

Duvelisib and Venetoclax in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)

  • David Geffen School of Medicine at the University of California at Los Angeles, Los Angeles
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Jul 17, 2026 · NCT06810778

Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial

  • Chao Family Comprehensive Cancer Center, University of California Irvine, Orange
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Jul 14, 2026 · NCT06580002

Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome

  • UCLA Department of Medicine, Los Angeles
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Jul 7, 2026 · NCT07216443

A Study of Revumenib and Mezigdomide in People With Leukemia

  • City of Hope Cancer Center (Data collection only), Duarte
RecruitingPhase 1/2
Ages 12 and older · All sexes · Updated Jun 22, 2026 · NCT07356154

A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas

  • Dren Investigational Site, Duarte
  • Dren Investigational Site, Irvine
  • Dren Investigational Site, Redwood City
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Jun 17, 2026 · NCT05475925

Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment

  • City of Hope Comprehensive Cancer Center, Duarte
  • Kaiser Permanente-Oakland, Oakland
  • Lucile Packard Children's Hospital Stanford University, Palo Alto
  • and 1 more
RecruitingObservational study
All ages · All sexes · Updated May 18, 2026 · NCT01790152

A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)

  • Keck School of Medicine of USC, Los Angeles
  • UC Irvine Health - Chao Family Comprehensive Cancer Center, Orange
RecruitingPhase 2/3
Ages 18 and older · All sexes · Updated Apr 30, 2026 · NCT04256317

The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies

  • City of Hope, Duarte
  • Los Angeles Cancer Network, Los Angeles
  • UCLA Medical Center of Hematology/Oncology, Los Angeles
  • and 1 more
RecruitingPhase 1/2
Ages 12 to 95 · All sexes · Updated Apr 15, 2026 · NCT04329728

A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML

  • Moores UC San Diego Cancer Center, La Jolla
  • USC / Norris Comprehensive Cancer Center, Los Angeles
  • UCLA - Bowyer Oncology Center, Los Angeles
  • and 1 more
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Mar 13, 2026 · NCT05735184

cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease

  • City of Hope, Duarte
RecruitingObservational studyHealthy volunteers welcome
Ages 40 and older · All sexes · Updated Jan 20, 2026 · NCT05366881

Study of NMS-03597812 in Adult Patients With Relapsed/Refractory Acute Myeloid Leukemia

  • City of Hope - Duarte, Duarte
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 31, 2025 · NCT06549790

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

  • Massive Bio SYNERGY-AI site, Duarte
  • Massive Bio SYNERGY-AI site, Irvine
  • Massive Bio SYNERGY-AI site, La Jolla
  • and 3 more
RecruitingObservational study
All ages · All sexes · Updated Oct 28, 2025 · NCT03452774

A Randomized Phase II Study Of Bruton Tyrosine Kinase Inhibitor With Or Without Venetoclax In Veterans With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

  • San Francisco VA Medical Center, San Francisco, CA, San Francisco
RecruitingPhase 2
Ages 18 to 80 · All sexes · Updated Oct 14, 2025 · NCT06520098

A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic Syndrome

  • City of Hope Medical Center, Duarte
  • University of California Los Angeles, Los Angeles
  • Stanford Cancer Center, Palo Alto
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 24, 2025 · NCT06501196

Effects of Using a Storybook, to Explain Leukemia to Children Versus the Standard Child Life Intervention, on Parental Stress.

  • Children's Hospital Los Angeles, Los Angeles
RecruitingHealthy volunteers welcome
Ages 3 and older · All sexes · Updated Aug 3, 2025 · NCT06360718

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.